REFERENCES
  1. Thomson Reuters. (August 04, 2015). Global pharma sales to reach $1.3 trillion.
  2. Centers for Medicare & Medicaid Services. Medicare-Medicaid Coordination. www.cms.gov. (Accessed September 2016)
  3. Centers for Medicare & Medicaid Services. Off-label Pharmaceutical Marketing: How to Recognize and Report It. www.cms.gov. (Accessed November 2016)
  4. John Braithwaite. (1984). Corporate crime in the pharmaceutical industry. Routledge & Kegan Paul. London, Boston, Melbourne and Henley.
  5. Thomas Gryta. (July 21, 2011). What is a ‘Pharmacy Benefit Manager?’. The Wall Street Journal.
  6. The United States Department of Justice (DOJ). Johnson & Johnson to Pay More Than $2.2 Billion to Resolve Criminal and Civil Investigations. www.justice.gov (Accessed October 2016)
  7. The United States Department of Justice (DOJ). July 2, 2012. GlaxoSmithKline to Plead Guilty and Pay $3 Billion to Resolve Fraud Allegations and Failure to Report Safety Data. www.justice.gov (Accessed November 2016).
  8. The United States Department of Justice (DOJ). July 2, 2012. AstraZeneca and Cephalon to Pay $46.5 Million and $7.5 Million, Respectively, for Allegedly Underpaying Rebates Owed Under Medicaid Drug Rebate Program. www.justice.gov (Accessed November 2016).
  9. The National Law Review. June 27, 2014. Omnicare Pays $124 Million to Settle Whistleblower Allegations Involving Healthcare Fraud.